For the year ending 2025-12-31, LGND made $268,087K in revenue. $124,453K in net income. Net profit margin of 46.42%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue and income | 268,087 | - | ||
| Cost of captisol | 14,549 | - | ||
| Amortization of intangibles | 32,708 | - | ||
| Research and development | 81,182 | - | ||
| General and administrative | 92,449 | - | ||
| Financial royalty assets impairment | 6,197 | - | ||
| Fair value adjustments to partner program derivatives | 0 | - | ||
| Total operating costs and expenses | 227,085 | - | ||
| Gain on sale of pelican | 0 | - | ||
| Operating income (loss) from continuing operations | 41,002 | -22,606 | ||
| Gain from short-term investments | 18,433 | 75,024 | ||
| Gain (loss) from change in fair value of equity method investments and other investments | 90,670 | - | ||
| Interest income | 13,659 | 8,055 | ||
| Interest expense | 4,715 | 3,037 | ||
| Other non-operating expense, net | -89 | -54,918 | ||
| Total non-operating income, net | 117,958 | 25,124 | ||
| Income before income tax from continuing operations | 158,960 | 2,518 | ||
| Income tax expense | 34,507 | 6,550 | ||
| Net income (loss) from continuing operations | 124,453 | -4,032 | ||
| Net income (loss) | 124,453 | -4,032 | ||
| Basic EPS | 6.44 | -0.22 | ||
| Diluted EPS | 6.13 | -0.22 | ||
| Basic Average Shares | 19,338,000 | 18,290,000 | ||
| Diluted Average Shares | 20,294,000 | 18,290,000 | ||
LIGAND PHARMACEUTICALS INC (LGND)
LIGAND PHARMACEUTICALS INC (LGND)